Indacaterol/mometasone
| Combination of | |
|---|---|
| Indacaterol | Beta-2 adrenergic receptor agonist |
| Mometasone | Corticosteroid |
| Clinical data | |
| Trade names | Atectura Breezhaler, Bemrist Breezhaler |
| Other names | QMF149, IND/MF |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[1]
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[1] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[1] and in Japan in June 2020.[2]
References
- 1 2 3 4 5 "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options". Novartis (Press release). 29 June 2020. Retrieved 25 July 2020.
External links
- "Indacaterol mixture with mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
| Adrenergics, inhalants |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoids | |||||||||
| Anticholinergics/ muscarinic antagonist | |||||||||
| Mast cell stabilizers | |||||||||
| Xanthines | |||||||||
| Eicosanoid inhibition |
| ||||||||
| Others/unknown | |||||||||
| Combination products |
| ||||||||
| |||||||||
| Glucocorticoids |
| ||||
|---|---|---|---|---|---|
| Antiglucocorticoids |
| ||||
| Synthesis modifiers | |||||
| |||||
Glucocorticoid receptor modulators | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| GR |
| ||||||||
| |||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.